These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28980665)

  • 1. Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease.
    Holmes MV; Smith GD
    Nat Rev Cardiol; 2017 Nov; 14(11):635-636. PubMed ID: 28980665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
    Nicholls SJ
    Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CETP inhibition.
    Duriez P
    Lancet; 2007 Dec; 370(9603):1882-3. PubMed ID: 18068495
    [No Abstract]   [Full Text] [Related]  

  • 5. HDL and Reverse Cholesterol Transport Biomarkers.
    Riggs KA; Rohatgi A
    Methodist Debakey Cardiovasc J; 2019; 15(1):39-46. PubMed ID: 31049148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial watch: hope renewed for strategy to raise HDL cholesterol.
    Nat Rev Drug Discov; 2011 Jan; 10(1):10. PubMed ID: 21193857
    [No Abstract]   [Full Text] [Related]  

  • 7. Dyslipidaemia: Is CETP inhibition a viable therapeutic strategy?
    Fernández-Ruiz I
    Nat Rev Cardiol; 2017 Jul; 14(7):382-383. PubMed ID: 28569268
    [No Abstract]   [Full Text] [Related]  

  • 8. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New horizons for cholesterol ester transfer protein inhibitors.
    Schwartz GG
    Curr Atheroscler Rep; 2012 Feb; 14(1):41-8. PubMed ID: 22083134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel HDL-based therapeutic agents.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):18-30. PubMed ID: 22465158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
    Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 14. Trials and Tribulations of CETP Inhibitors.
    Tall AR; Rader DJ
    Circ Res; 2018 Jan; 122(1):106-112. PubMed ID: 29018035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
    Nicholls SJ; Nelson AJ
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):229-235. PubMed ID: 30610681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targets to raise HDL in patients at risk or with coronary artery disease.
    Lüscher TF; von Eckardstein A; Simic B
    Curr Vasc Pharmacol; 2012 Nov; 10(6):720-4. PubMed ID: 23259565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DEFINE study: a bright future for CETP inhibitors?
    Katsiki N; Athyros VG; Mikhailidis DP
    Expert Opin Investig Drugs; 2011 Mar; 20(3):311-4. PubMed ID: 21235422
    [No Abstract]   [Full Text] [Related]  

  • 18. Evacetrapib.
    Nicholls SJ
    Curr Cardiol Rep; 2012 Jun; 14(3):245-50. PubMed ID: 22362199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.